Amphastar Pharmaceuticals (AMPH) Gross Profit Margin: History & Chart

Amphastar Pharmaceuticals, Inc.(AMPH)

Drug Manufacturers - Specialty & Generic · Rancho Cucamonga, CA

$25.37-0.06 (-0.24%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Rancho Cucamonga, CA

1,976 employees

www.amphastar.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Yongfeng Zhang

View full financials

AMPH Gross Margin Metrics

GROSS MARGIN

47.68%

GROSS MARGIN AVG TTM

47.94%

GROSS MARGIN AVG 3Y

50.54%

GROSS MARGIN AVG 5Y

49.89%

GROSS MARGIN AVG 10Y

44.75%

GROSS MARGIN AVG 15Y

N/A

GROSS MARGIN AVG 20Y

N/A

CURRENT VS TTM AVG

-0.54%

CURRENT VS 3Y AVG

-5.66%

CURRENT VS 5Y AVG

-4.42%

CURRENT VS 10Y AVG

+6.55%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

42.91%

median of 438 covered companies

CURRENT VS SECTOR MEDIAN

+11.12%

vs the sector median at left

NAME	MARKET CAP	GROSS MARGIN	TTM	3Y	5Y
Amphastar Pharmaceuticals, Inc. (AMPH)	$1.12B	47.68%	47.94%	50.54%	49.89%
Castle Biosciences, Inc. (CSTL)vs ›	$1.12B	77.26%	80.62%	79.35%	80.86%
Bicara Therapeutics Inc. Common Stock (BCAX)vs ›	$1.14B	0.00%	0.00%	0.00%	0.00%
Harrow Health, Inc. (HROW)vs ›	$1.14B	73.28%	75.19%	72.82%	72.76%
GoodRx Holdings, Inc. (GDRX)vs ›	$1.16B	88.05%	93.34%	92.32%	92.94%
Teladoc Health, Inc. (TDOC)vs ›	$1.05B	73.53%	70.13%	70.04%	68.74%
Avalyn Pharma Inc. Common Stock (AVLN)vs ›	$1.20B	0.00%	0.00%	0.00%	0.00%
Immatics N.V. (IMTX)vs ›	$1.04B	100.00%	100.00%	100.00%	64.23%
Integra LifeSciences Holdings Corporation (IART)vs ›	$1.03B	53.74%	53.23%	56.54%	58.23%
Cronos Group Inc. (CRON)vs ›	$1.21B	36.16%	31.39%	23.56%	1.95%

NAME

MARKET CAP

GROSS MARGIN

TTM

Amphastar Pharmaceuticals, Inc. (AMPH)

$1.12B

47.68%

47.94%

50.54%

49.89%

Castle Biosciences, Inc. (CSTL)vs ›

$1.12B

77.26%

80.62%

79.35%

80.86%

Bicara Therapeutics Inc. Common Stock (BCAX)vs ›

$1.14B

0.00%

Harrow Health, Inc. (HROW)vs ›

$1.14B

73.28%

75.19%

72.82%

72.76%

GoodRx Holdings, Inc. (GDRX)vs ›

$1.16B

88.05%

93.34%

92.32%

92.94%

Teladoc Health, Inc. (TDOC)vs ›

$1.05B

73.53%

70.13%

70.04%

68.74%

Avalyn Pharma Inc. Common Stock (AVLN)vs ›

$1.20B

0.00%

Immatics N.V. (IMTX)vs ›

$1.04B

100.00%

64.23%

Integra LifeSciences Holdings Corporation (IART)vs ›

$1.03B

53.74%

53.23%

56.54%

58.23%

Cronos Group Inc. (CRON)vs ›

$1.21B

36.16%

31.39%

23.56%

1.95%

Gross Margin FAQ

What is the gross margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The gross margin for AMPH stock is 47.68%.

Is Amphastar Pharmaceuticals, Inc.'s gross margin high or low?

The gross margin of 47.68% is in line with its 5-year average of 49.89%, around the middle of its 5-year range (41.08%–60.04%).

What is the TTM average gross margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The TTM average gross margin for AMPH stock is 47.94%.

What is the 3Y average gross margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 3Y average gross margin for AMPH stock is 50.54%.

What is the 5Y average gross margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 5Y average gross margin for AMPH stock is 49.89%.

What is the 10Y average gross margin for Amphastar Pharmaceuticals, Inc. (AMPH)?

The 10Y average gross margin for AMPH stock is 44.75%.

DATE	GROSS MARGIN
2026-06-30	50.83%
2026-03-31	41.08%
2025-12-31	46.79%
2025-09-30	51.42%
2025-06-30	49.59%
2025-03-31	49.99%
2024-12-31	46.45%
2024-09-30	53.99%
2024-06-30	52.18%
2024-03-31	50.80%
2023-12-31	53.98%
2023-09-30	60.04%
2023-06-30	49.92%
2023-03-31	52.73%
2022-12-31	52.71%
2022-09-30	48.71%
2022-06-30	51.31%
2022-03-31	46.38%
2021-12-31	46.52%
2021-09-30	45.62%
2021-06-30	46.60%
2021-03-31	43.63%
2020-12-31	38.40%
2020-09-30	43.76%
2020-06-30	38.67%
2020-03-31	43.48%
2019-12-31	40.03%
2019-09-30	43.99%
2019-06-30	40.97%
2019-03-31	38.73%
2018-12-31	38.68%
2018-09-30	38.73%
2018-06-30	36.82%
2018-03-31	29.22%
2017-12-31	34.07%
2017-09-30	35.64%
2017-06-30	41.03%
2017-03-31	40.28%
2016-12-31	31.41%
2016-09-30	42.99%
2016-06-30	46.62%
2016-03-31	41.95%
2015-12-31	43.13%
2015-09-30	27.52%
2015-06-30	24.73%
2015-03-31	23.34%
2014-12-31	21.41%
2014-09-30	19.75%
2014-06-30	30.60%
2014-03-31	27.27%
2013-12-31	35.77%
2013-09-30	34.19%
2013-06-30	43.97%
2013-03-31	36.93%
2012-12-31	41.83%

DATE

GROSS MARGIN

2026-06-30

50.83%

2026-03-31

41.08%

2025-12-31

46.79%

2025-09-30

51.42%

2025-06-30

49.59%

2025-03-31

49.99%

2024-12-31

46.45%

2024-09-30

53.99%

2024-06-30

52.18%

2024-03-31

50.80%

2023-12-31

53.98%

2023-09-30

60.04%

2023-06-30

49.92%

2023-03-31

52.73%

2022-12-31

52.71%

2022-09-30

48.71%

2022-06-30

51.31%

2022-03-31

46.38%

2021-12-31

46.52%

2021-09-30

45.62%

2021-06-30

46.60%

2021-03-31

43.63%

2020-12-31

38.40%

2020-09-30

43.76%

2020-06-30

38.67%

2020-03-31

43.48%

2019-12-31

40.03%

2019-09-30

43.99%

2019-06-30

40.97%

2019-03-31

38.73%

2018-12-31

38.68%

2018-09-30

38.73%

2018-06-30

36.82%

2018-03-31

29.22%

2017-12-31

34.07%

2017-09-30

35.64%

2017-06-30

41.03%

2017-03-31

40.28%

2016-12-31

31.41%

2016-09-30

42.99%

2016-06-30

46.62%

2016-03-31

41.95%

2015-12-31

43.13%

2015-09-30

27.52%

2015-06-30

24.73%

2015-03-31

23.34%

2014-12-31

21.41%

2014-09-30

19.75%

2014-06-30

30.60%

2014-03-31

27.27%

2013-12-31

35.77%

2013-09-30

34.19%

2013-06-30

43.97%

2013-03-31

36.93%

2012-12-31

41.83%

Gross Margin: 47.68%

AMPH Gross Margin

AMPH Average Gross Margin Chart

AMPH Current vs Average Gross Margin Chart

AMPH Gross Margin Metrics

AMPH Competitors' Gross Margin

Gross Margin Analysis

Gross Margin Formula & Definition

Gross Margin FAQ

AMPH Gross Margin History

Related Metrics